1 Urine lipoarabinomannan concentrations among HIV-

2 uninfected adults with pulmonary or extrapulmonary

3 tuberculosis disease in Vietnam

- 5 Nguyen B. Hoa¹⁺, Mark Fajans²⁺, Hung Nguyen Van¹, Bao Vu Ngoc³, Nhung Nguyen Viet¹, Hoa Nguyen
- 6 Thi¹, Lien Tran Thi Huong³, Dung Tran Minh³, Cuong Nguyen Kim¹, Trinh Ha Thi Tuyet¹, Tri Nguyen Huu¹,
- 7 Diep Bui Ngoc⁴, Hai Nguyen Viet¹, An Tran Khanh³, Lorraine Lillis⁵, Marcos Perez⁵, Katherine K. Thomas⁹,
- 8 Roger B. Peck⁵, Jason L. Cantera⁶, Eileen Murphy⁵, Olivia R. Halas⁵, Helen L. Storey⁵, Abraham Pinter⁷,
- 9 Morten Ruhwald⁸, Paul K. Drain^{2,9,10}, David S. Boyle^{5*}
- 10
- 11 ¹ National Lung Hospital, Hanoi, Vietnam
- 12 ² Department of Epidemiology, University of Washington, Seattle, USA
- 13 ³ Southeast Asia Hub, PATH, Hanoi, Vietnam
- 14 ⁴ Center for Creative Initiatives in Health and Population, Hanoi, Vietnam
- 15 ⁵ Diagnostics Global Program, PATH, Seattle, USA
- 16 ⁶ Global Health Labs, Bellevue, USA
- 17 ⁷ Public Health Research Institute Center, New Jersey Medical School, Rutgers University, USA
- 18 ⁸ TB Program, Foundation for Innovative New Diagnostics, Geneva, Switzerland
- ⁹ Department of Global Health, University of Washington, Seattle, USA
- 20 ¹⁰ Department of Medicine, University of Washington, Seattle, USA
- 21
- 22 ⁺ Both authors contributed equally to this work
- 23 * Corresponding author (DSB): <u>dboyle@path.org</u>
- 24

25 Abstract

26	Lipoarabinomannan (LAM) is a Mycobacterial cell wall glycolipid excreted in urine, and a target
27	biomarker of rapid diagnostic tests (RDTs) for tuberculosis (TB) disease. Urine LAM (uLAM) testing by
28	RDT has been approved for people living with HIV, but there is limited data regarding uLAM levels in
29	HIV-negative adults with TB disease. We conducted a clinical study of adults presenting with TB-related
30	symptoms at the National Lung Hospital in Hanoi, Vietnam. The uLAM concentrations were measured
31	using electrochemiluminescent immunoassays and compared to a microbiological reference standard
32	(MRS) of sputum, GeneXpert Ultra and TB culture. Additional microbiological testing was conducted for
33	possible extrapulmonary TB, when clinically indicated. Among 745 participants enrolled, 335 (44.9 %)
34	participants recruited from the pulmonary TB wards (PR-PTBW) and 6 (11.3%) participants recruited
35	from the EPTB wards (PR-EPTBW) had confirmed TB disease. The MRS positive cohort measured median
36	uLAM concentration for S4-20/A194-01 (S/A) were 14.5 pg/mL and 51.5 pg/mL, respectively. The
37	FIND28/A194-01 (F/A) antibody pair overall and TB-positive cohort measured mean uLAM was 44.4
38	pg/mL and 78.1 pg/mL, respectively. Overall, the S/A antibody pair had a sensitivity of 39% (95%
39	Confidence Interval [CI] 0.33, 0.44) and specificity of 97% (95% CI 0.96, 0.99) against the MRS. The F/A
40	antibody pair had a sensitivity of 41% (95% CI 0.35, 0.47) and specificity of 79% (95% CI 0.75, 0.84). The
41	areas under the receiver operating curves were 0.748 for S/A and 0.629 for F/A. There was little
42	difference between the S/A median uLAM concentration with pulmonary (55 pg/mL) and
43	extrapulmonary (36 pg/mL) TB disease. With F/A the medians for pulmonary and extrapulmonary TB
44	disease were 79% and 76.5% respectively. Among HIV-negative adults in Vietnam, concentrations of
45	uLAM remained relatively low for people with TB disease, which may present challenges for developing
46	a more sensitive rapid uLAM test.

47

48 Introduction

49	Tuberculosis (TB) remains one of the leading infectious causes of death worldwide. Most TB
50	infections occur among HIV-negative persons, but people living with HIV (PLWH) have a significantly
51	higher individual risk of TB disease and case fatality rate [1,2]. In 2022, approximately 40% of people
52	with TB disease were either not diagnosed or not reported to national disease surveillance systems [2].
53	Many people in TB-endemic settings may have limited access to care, and improved access to TB
54	diagnostics could improve treatment initiation and reduce mortality [3].
55	Lipoarabinomannan (LAM) is a pathogen biomarker that has clinical utility for diagnosing TB
56	disease [4]. LAM is a glycolipid in the Mycobacterial cell that is also secreted in exosomes and
57	subsequently excreted in urine [5,6]. Capped derivatives of LAM are TB specific and detectable in urine
58	[7–10]. The Alere Determine™ TB LAM Ag (Determine, Abbott Diagnostics, USA) is a rapid diagnostic test
59	(RDT) approved by the World Health Organization (WHO) for use among PLWH with immune
60	suppression and advanced disease [11–13]. However, this RDT is only approved for people with TB-
61	related symptoms who have a CD4 <200 cells/mm ³ [14]. As such, the only WHO-approved uLAM RDT has
62	insufficient sensitivity for HIV-uninfected people with TB disease.
63	Currently, there is limited data on the concentration of urine LAM (uLAM) in HIV-uninfected
64	adults with TB disease. Prior studies of uLAM concentrations used material predominantly from
65	mycobacterial culture. which differs structurally from in vivo isolated LAM [15,16]. Most clinical
66	validation studies using RDTs for uLAM have focused on PLWH and evaluated performance against
67	microbiological reference standards (MRS, culture and/or GeneXpert) [17,18]. One study described two
68	small cohorts from Peru and South Africa showed mixed results, and these were underpowered for HIV-
69	uninfected participants [19]. A scaled clinical evaluation of uLAM using an ultra-sensitive LAM
70	immunoassay has not been performed in HIV-uninfected adults. Our objective was to accurately

71	quantify the concentration of uLAM and evaluate clinical diagnostic accuracy among HIV-uninfected
72	adults presenting with TB-related symptoms using highly sensitive electrochemiluminescent (ECL)
73	immunoassays [20]. We included adults with both pulmonary and extrapulmonary TB in a high TB-
74	burden, low HIV setting of Hanoi, Vietnam.

75

76 Materials and Methods

77 Study Design and Participants

We conducted a prospective longitudinal cohort study of adults 18 years of age or older who 78 79 had TB-related symptoms and presented for routine care at the National Lung Hospital (Hanoi, Vietnam) 80 between October 2021 and April 2022. Presumptive participants recruited from the pulmonary TB ward 81 (PR-PTBW) were recruited from both outpatient clinic and hospitalized respiratory inpatient ward. 82 Presumptive participants recruited from the extra pulmonary TB (PR-EPTBW) ward were recruited from 83 an EPTB inpatient ward exclusively. Exclusion criteria included having received isoniazid preventive therapy within the previous 3 months, having received anti-TB treatment for more than 24 hours, or 84 85 having a confirmed TB diagnosis at time of recruitment. Details of study recruitment, eligibility and 86 exclusion criteria, and enrollment procedures are described in the supplementary materials. Eligibility 87 criteria were developed to be representative of people who may be evaluated for pulmonary or 88 extrapulmonary TB disease in Vietnam (see S1 Doc and S2 Doc).

89 Ethical approvals

90 The institutional review boards (IRBs) at the National Lung Hospital (NLH, Hanoi, Vietnam;
91 reference No: 26/21/CN-HDDD) and the Vietnam Ministry of Health (Hanoi, Vietnam; reference No:

92 95/CN-HDDD) approved the study and the PATH Office of Research Affairs (ORA) gave approval
93 contingent on the NLH IRB decision. Written informed consent was obtained from each eligible
94 participant prior to enrollment. The immunoassay testing at the PATH laboratory was determined as
95 non-human subjects research by the PATH ORA before any analysis was performed on the samples.

96 Study Procedures and Clinical Care

97 After enrollment, we collected sociodemographic and clinical history, and participants received 98 a clinical evaluation as part of the routine standard of care. If a participant did not have a documented 99 HIV test within the prior 6 months, then they were offered testing. HIV testing was offered using 100 Determine HIV-1/2 (Abbot Diagnostics, Scarborough, ME) or Quick Test HIV 1 & 2 (Amvi Biotech, Ho Chi 101 Minh City, Vietnam), and positive results confirmed with a second rapid test and finally an HIV ELISA 102 (Murex HIV Ag/Ab combination, DiaSorin, Saluggia, Italy). For PR-PTBW, we collected separate sputum 103 samples for Xpert MTB/RIF Ultra and MGIT liquid culture testing for all participants. For PR-EPTBW), we 104 collected non-respiratory samples (CSF, pleural fluid, etc.) for MGIT testing and Xpert MTB/RIF Ultra 105 testing, as clinically indicated. We obtained urine samples, which were frozen at -80 °C immediately 106 after collection and until the lab-based testing. At 2 and 6 months after enrollment, we conducted 107 follow-up phone calls to participants to evaluate clinical status and response to TB treatment, and 108 searched clinical chart and laboratory records to ascertain incident diagnoses, repeat hospitalization, or 109 treatment initiation. Approximately 30 mLs of urine from each participant was collected for analysis with 110 the ECL immunoassays and the remaining material was retained to create a biorepository at PATH for future access to developers of uLAM diagnostic products. 111

112 Evaluation of the clinical urine specimens using immunoassays

The concentration of uLAM in the urine specimens was measured using highly sensitive 113 114 electrochemiluminescent (ECL) immunoassays [20]. We separately evaluated two different monoclonal 115 capture antibodies, FIND28 (Foundation for Innovative New Diagnostics, Geneva, [20]) and S4-20 (Otsuka 116 Pharmaceuticals, Tokyo, Japan [21]), that were biotinylated (EZ-Link Sulfo-NHS-LC-Biotinylation Kit, 117 ThermoFisher Scientific, Waltham, MA, USA). For both capture antibodies, we used the same recombinant 118 detector antibody, A194-01 (Rutgers University [9]), which was labeled with the GOLD SULFO-TAG NHS-119 Ester (Mesoscale Diagnostics [MSD], Rockville, MD, USA). Unbound labels (biotin or SULFO-TAG) were 120 removed using desalting columns (40 kDa MWCO Zeba Spin, Thermo).

121 The biotinylated capture antibodies were coupled to U-PLEX plates (MSD) via biotin-streptavidin 122 binding to U-PLEX linkers (MSD). Both antibody-linker conjugates were mixed with U-PLEX stop buffer 123 (MSD) at a concentration of 0.29 μg/mL and 50 μL added to each well. Plates were incubated for 1 hour 124 with shaking at 500 rpm to allow for the antibodies to self-assemble to their discrete and complimentary 125 linker-binding sites to create a 2-plex immunoarray. Plates were washed 3X with 300 μL/well of 1X 126 phosphate buffered saline + 0.05% Tween 20 (PBS-T, pH 7.5) using a ELX405R microplate washer (BioTek 127 Instruments Inc., Winooski, VT).

128 The analysis of uLAM was performed by adding 25 µL of Buffer 22 (MSD) to each well followed 129 by 25 µL of unconcentrated urine sample, standard, or control [20]. Plates were incubated at room 130 temperature with shaking for 1 hour at 500 rpm to allow binding of uLAM to the capture antibodies. 131 Plates were washed 3X with PBS-T and then 25 μ L of SULFO-TAG detection antibody (2 μ g/mL) in 132 Diluent 3 (MSD) was added to each well with shaking for 1 hour. Plates were washed 3X with PBS-T and 133 filled with 150 µL of 2X read buffer T (MSD) per well. The plates were read in a MESO QuickPlex SQ 120 134 plate reader (MSD) and the ECL from each individual array spot were measured and analyzed using the 135 Discovery Workbench v4 software (MSD). The LAM used for the standard curve was derived from the in 136 vitro culture of the TB strain Aoyama B (Nacalai USA, Inc., San Diego, CA) was dissolved in 1% BSA in

water (w/v). Duplicate seven-point serial dilutions of the TB LAM stock (40,000 pg/ml to 2.44 pg/mL) in
2% BSA/1X PBS with a negative control were used to generate calibration curves.

139 The relationship of ECL to LAM concentration was fitted to a four-parameter logistic (4-PL) 140 function. The uLAM concentration in each specimen was then calculated for both antibody pairs by 141 back-fitting the ECL data to the 4-PL fit using proprietary software from MSD. A specimen was 142 considered detected when the ECL signal of the sample correlated with signals above the limit of 143 detection in the assay (LOD) determined from the software. The LOD was calculated by the software, 144 based on signal generated by the calibrators and negative control and deviated slightly from plate to 145 plate (S1 Table). As such we used the LOD established from each plate to score the test results and so 146 afford greater accuracy, as opposed to earlier approaches of applying universal cutoff values [19,20]. 147 Anything below the LOD was considered not detected. In cases where samples containing uLAM was above the upper limit of detection, then the sample was diluted in 1X PBS and reassessed. 148

149 Reference Standards

150 The microbiological reference standard (MRS) was defined as having a positive result by either 151 Xpert Ultra or Mycobacterial culture by MGIT. For PR-PTBW, a positive microbiological test result using a 152 respiratory (sputum) specimen was required, while both a negative Xpert Ultra and MGIT culture result 153 using a respiratory specimen was required to be considered negative. Two separate sputum samples 154 were collected consecutively for Xpert Ultra and MGIT testing. The MRS for EPTB included tissue 155 samples from pleura, lymph nodes, abdomen, or meninges. Due to the difficulty in using non-respiratory 156 specimen for Xpert testing, when no Xpert testing was done for non-respiratory specimen, a negative 157 EPTB cases would consist of a negative culture using a non-respiratory specimen. The clinical reference 158 standard (CRS) was defined as either meeting the MRS definition or receiving empiric TB treatment (+/-159 compatible chest X-ray) within 2 months of enrollment at the discretion of the treating clinicians.

160 Statistical Analyses

161	We report diagnostic accuracy of the ECL immunoassays via sensitivity, specificity, positive and
162	negative predictive values, and positive and negative likelihood ratios, along with 95% confidence
163	intervals estimated using the binomial exact (Clopper-Pearson) method. The primary reference standard
164	was the MRS, with Xpert result alone, culture result alone and CRS reference standards presented for
165	additional information. Comparison of sensitivities or specificities between the PR-PTBW and PR-EPTBW
166	groups were made using Fisher's exact test. Comparisons of sensitivities or specificities between mAb
167	pairs within the same TB group were made using McNemar test. Receiver operating characteristic (ROC)
168	curves were calculated to evaluate the overall discriminatory ability of each antibody (Ab) pair, and
169	statistically compared using paired or unpaired ROC comparisons (R package pROC, v1.18), as
170	appropriate [22]. We conducted all analyses using R version 4.1.2 [23]. All of the data generated in this
171	study can be publicly accessed at Dataverse (https://doi.org/10.7910/DVN/AOL0LP).

172

173 Results

174 We enrolled 780 participants from the wards (700 people with presumed PTB [PR-PTBW] and 80 people 175 with presumed EPTB PR-EPTBW]). Of these, 11 participants were excluded due to the urine collection 176 not being within 48 hours of enrollment, and 3 were excluded due to being HIV-positive, leaving 766 177 participants being evaluated by the MRS (693 PR-PTBW, 73 PR-EPTBW; Figure 1). From the PR-PTBW 178 group, 1 participant could not be validated due to culture being available only on an extrapulmonary 179 specimen (pleural fluid). From the PR-EPTBW group, 20 participants could not be validated because non-180 pulmonary specimens were not available for validation testing. Of these, 15 had only a pulmonary 181 sample collection for validation, one had only respiratory (sputum) specimen collected for Xpert testing

- and none for MGIT testing, and four had no sample collected for Xpert or MGIT testing. The reasons for
- 183 missing samples on these four were that no sample fluids were available for collection from cases of
- 184 presumed spinal TB, presumed intestinal TB and presumed bone TB respectively. A total of 692
- 185 PR=PTBW and 53 PR-EPTBW participants were included in our analyses.
- 186

187 Figure 1. A STARD accuracy flowchart of the recruitment and diagnostic classification of the study

188 **subjects from October 2021 to April 2022.** HIV, human immunodeficiency virus; PR-PTBW, PResumed

189 Pulmonary TuBerculosis from the Wards; PR-EPTBW, PResumed Extra Pulmonary TuBerculosis from the

190 Wards; Xpert, GeneXpert MTB/RIF Ultra.

191

192 Overall, the participants were predominantly male (66.7%), older (mean= 46.7 years, SD=16.0) 193 and 6% self-reported a history of recent TB exposure (Table 1). The most commonly reported symptoms 194 among the PR-PTBW group included prolonged cough (88.9%), weight loss (64.5%) and fatigue (67.6%), 195 with fewer participants reporting prolonged fever (23.0%). High proportions of participants in the PR-196 EPTBW group reported typical presumptive TB symptoms (prolonged cough, fever, nights sweats, 197 weight loss and fatigue). Chest X-ray (CXR) indicative of TB disease was seen in 21.8% of PR-PTBW with 198 chest X-rays and 7.5% of PR-EPTBW. The majority (81.1%) of PR-PTBW were AFB smear negative, and 199 among smear positive, nearly half had a bacterial load graded as scanty or 1+. Positivity by MGIT liquid 200 culture was 40.5% in the PR-PTBW group and only 5.7% in the PR-EPTBW group. Xpert Ultra positivity 201 was 43.3% in PR-PTBW, and 22.7% (5/22) in the subset of PR-EPTBW with Xpert Ultra. Overall, 335 202 (48.5%) of PR-PTBW and just 6 (11.3%) PR-EPTBW were microbiologically confirmed as TB positive. Using 203 the CRS, 414 (59.8%) of PR-PTBW and 33 (62.3%) of PR-EPTBW were considered TB positive. MGIT also 204 identified 35 participants as having an infection with nontuberculous mycobacteria (NTM).

205 Table 1. Characteristics of enrolled HIV negative participants with presumptive pulmonary and

- 206 **extrapulmonary TB (inpatient and outpatient recruitment, N= 745).** * Captured by question "Currently
- 207 living with someone with confirmed TB diagnosis?"; **496 participants with available CXR results (444 PR-PTBW,
- 208 52 PR-EPTBW); ***22 PR-EPTBW participants with non-sputum samples; denominator for PR-PTBW cohort is
- 209 participants with a pulmonary specimen collected for testing, while for PR-EPTBW group is participants with a
- 210 non-pulmonary specimen collected; ****Participants with inadequate specimen, NTM or not ordered set to
- 211 missing for culture only reference standard.

		Presumptive pulmonary TB Patients (n=692)	Presumptive Extrapulmonary TB Patients (n=53)	Total (N=745)
Demographics				
Female Sex, n (%)		231 (33.4)	17 (32.1)	248 (33.3)
Age, mean (SD)		46.6 (15.9)	48 (17.2)	46.7 (16.0)
Hospitalization status, n (%)				
	Inpatient	178 (25.7)	53 (100)	231 (31.0)
	Outpatient	514 (74.3)	0 (0)	514 (69.0)
Symptom presentation, n (%)				
	Cough	615 (88.9)	44 (83)	659 (88.5)
	Fever	159 (23.0)	43 (81.1)	202 (27.1)
	Night sweats	159 (23.0)	42 (79.2)	201 (27.0)
	Weight Loss	446 (64.5)	52 (98.1)	498 (66.8)
	Fatigue	468 (67.6)	53 (100)	521 (69.9)
History of recent TB exposure*, n (%)				
	Yes	43 (6.2)	2 (3.8)	45 (6.0)
	No	641 (92.6)	51 (96.2)	692 (92.9)
	Don't Know	8 (1.2)	0 (0)	8 (1.1)
Chest X-Ray Indicative of TB ⁺⁺ , n (%)		97 (21.8)	4 (7.5)	101 (20.3)
AFB smear positive, n (%)		131 (18.9)	0 (0)	131 (17.6)
AFB smear positivity, n (%)	Scanty	12 (9.1)	0 (0)	12 (9.1)
	1+	65 (49.6)	0 (0)	65 (49.6)
	2+	32 (24.4)	0 (0)	32 (24.4)
	3+	22 (16.8)	0 (0)	22 (16.8)
Xpert Ultra positive***, n (%)		300 (43.3)	5 (22.7)	305 (42.7)
Rif resistance detected, n (%)		12 (4.0)	0 (0)	12 (1.6)
MGIT liquid culture positivity, n (%)				
	Positive	280 (40.5)	3 (5.7)	283 (37.9)
	NTM	35 (5.1)	0 (0)	35 (4.7)
	375 (54.2)	50 (94.3)	425 (50.3)	
Specimen contamination	Specimen contamination/not ordered			2 (0.3)
Microbiological Reference Standard, n (9	335 (48.5)	6 (11.3)	341 (45.8)	
Xpert Ultra positive***, n (%)		300 (43.4)	5 (22.7)	305 (42.7)
Culture positive****, n (%)		280 (42.7)	3 (5.7)	283 (40.0)
Clinical Reference Standard, n (%)		414 (59.8)	33 (62.3)	447 (60.0)

212

The analysis of the uLAM concentrations showed the FIND 28:A194-01 (F/A) Ab pair had a greater number of positive tests in both PR-PTBW and PR-EPTBW cohorts (Table 2). A similar percentile of PR-PTBW and PR-EPTBW had uLAM were detected via F/A (30.6% vs 34.0%, *p*=0.643) and also S4-

216	20/A194-01 (S/A; 20.1% vs 15.1%, <i>p</i> =0.475) when not stratifying by MRS status. When pooled, F/A
217	detected positivity was 230 (30.9%) while S/A was 147 (19.7%). Among participants with uLAM detected
218	by F/A, the median estimated uLAM concentration was similar with PR-PTBW at 79.0 pg/mL
219	(interquartile range [IQR] 31.8 - 290.5), and 76.5 pg/mL (IQR 34.3-190.0) for PR-EPTBW. When stratifying
220	by MRS status, median estimated uLAM concentration appeared higher for MRS-positive PR-PTBW
221	(110.0 pg/mL vs. 45.0 pg/mL) compared to MRS-negative PR-PTBW, higher among MRS-negative
222	compared to MRS-positive PR-EPTBW (44.0 pg/mL vs 77.0 mg/mL). Among participants with uLAM
223	detected in their urine using the S/A pair, the median estimated uLAM concentration among PR-PTBW
224	was 55.0 pg/mL, (IQR 27.0 - 139.5), and 36.0 pg/mL (IQR 29.0-46.3) for PR-EPTBW. When stratifying by
225	MRS status, median estimated uLAM concentration appeared higher for MRS-positive PR-PTBW (57.0
226	pg/mL vs. 21.0 pg/mL) compared to MRS-negative PR-PTBW, as well as for PR-EPTBW (50.5 pg/mL vs.
227	33.0 pg/mL) respectively. When viewing the distribution of estimated uLAM concentrations for the same
228	participants using the two antibody pairs, the F/A pair appears to estimate a higher concentration of
229	78.0 pg/mL as compared to the S4-20:A194-01 Ab pair with 51.0 pg/mL (Table 2 and Figure 2). Only 87
230	(32.9%) PR-PTBW and 5 (23.8%) PR-EPTBW were uLAM positive by both F/A and S/A pairs, indicating a
231	high degree of discordant detection (S1 Fig).

233 Table 2. ECL test results of study participants using S/A and F/A Ab pairs (N=745). The number of S/A

- and F/A positive results for both PR-PTBW and PR-EPTBW, and the pooled data with the median uLAM
- 235 concentration (pg/mL) among participants with detected uLAM. Abbreviations: PR-PTBW, presumptive
- 236 pulmonary TB from ward; PR-EPTBW, presumptive extra pulmonary TB from ward; MRS, microbiological
- reference standard; ECL, electrochemiluminescent; S/A, S4-20/A194-01 Ab pair; N, number; F/A,

238 FIND28/A194-01 Ab pair. IQR, interquartile range.

	PR-PTBW	/ (N=692)	PR-EPTBV	Pooled	
	MRS + (n=335)	MRS - (n=357)	MRS + (n=6)	MRS – (n=47)	(N=745)
S/A positive result – N (%)	130 (38.8)	9 (2.5)	2 (33.3)	6 (12.8)	147 (19.7)
S/A Median uLAM conc. – pg/mL (IQR)	57.0.0 (29.0- 150.0)	21.0 (17.0 – 26.0)	50.5 (50.25 – 50.75)	33.0 (23.0 – 37.0)	51.0 (27.0 – 125.0)
F/A Positive result – N (%)	137 (40.9)	75 (21.0)	3 (50.0)	15 (31.9)	230 (30.9)
F/A Median uLAM conc. – pg/mL (IQR)	110.0 (36.0- 374.0))	45.0 (29.5 – 104.0)	44.0 (30.5- 93.0))	33.0 (23.0 – 37.0)	78.0 (31.2 – 284.0)

239

240	Figure 2. The range of uLAM concentrations quantitated by the ECL immunoassay using antibody pairs
241	S/A and F/A (N=745).

242 When evaluating the diagnostic performance of uLAM detection using the S/A pair the overall 243 senstivity was low in this HIV negative population. A similar proportion of microbiologically confirmed 244 participants were correctly identified in PR-PTBW (sensitivity: 39%, 95% CI: 34-44%) and PR-EPTBW 245 (sensitivity: 33%, 95% CI: 4-78%), (Table 3). However, true negatives were more accurately identified in 246 PR-PTBW (specificity: 97%, 95% CI: 95-99%) compared to PR-EPTBW (specificity: 87%, 95% CI: 74-95%). 247 When using the CRS as the reference standard instead, test sensitivity was 32% (95% CI: 28-37%) in PR-248 PTBW and 24% (95% CI: 11 - 42%) in the PR-EPTBW, and specificity was very similar in both groups at 249 98%-100%. When the immunoassay data for S/A and F/A was pooled and also compared to the MRS, Xpert Ultra, MGIT and CRS data for both PR-PTBW (S2 Table) and PR-EPTBW (S3 Table). The sensitivity 250 251 for PR-PTBW was 55% (95% CI: 0.490.60%) and the specificity was 78% (95% CI: 0.73-0.82%). With the

252 PR-EPTBW group, sensitivity was similar at 50% (95% CI: 0.12-0.88%) and with a specificity of 62% (95%

253 CI: 0.46-0.75%).

Table 3. The diagnostic sensitivity and specificity of the ECL S/A and & F/A immunoassays in the PR-

255 PTBW and PR-EPTBW groups as compared to the microbiologic reference standards (MRS), Xpert,

256 MGIT, and the clinical reference standard (CRS) used in the diagnosis of TB disease. The positive

257 predictive values (PPV), negative predictive values (NPV), positive likelihood ratios (PLR) and negative

likelihood ratios (NLR) were also calculated for each. Abbreviations: N, number; TP, true positive; TN,

true negative; FN, false negative; FP, false positive; CI, confidence interval; S/A, S4-20/A194-01; F/A,

260 FIND28/A194-01; PR-PTBW, presumed pulmonary tuberculosis from ward; MGIT, mycobacterial growth

261 indicator tube; MRS, microbiological reference standard; CRS, clinical reference standard; PR-EPTBW,

		Positive b star	y reference ndard	erence Negative by reference standard					
Reference Standard	N	TP/TP+FN	Sensitivity (95% CI)	TN/TN+FP	Specificity (95% Cl)	PPV (95% Cl)	NPV (95% CI)	PLR (95% CI)	NLR (95% CI)
S/A PR-PTBW						•			•
MRS	692	130/335	0.39 (0.34, 0.44)	348/357	0.97 (0.95, 0.99)	0.94 (0.88, 0.97)	0.63 (0.59, 0.67)	15.4 (7.96, 29.75)	0.63 (0.58, 0.68)
Xpert Ultra	692	123/300	0.41 (0.35, 0.47)	376/392	0.96 (0.93, 0.98)	0.88 (0.82, 0.93)	0.68 (0.64, 0.72)	15.4 (7.96, 29.75)	0.62 (0.56, 0.68)
MGIT ^{\$}	655	112/280	0.40 (0.34, 0.46)	356/375	0.95 (0.92, 0.97)	0.95 (0.92, 0.97)	0.68 (0.64, 0.72)	7.89 (4.98, 12.52)	0.63 (0.57, 0.70)
CRS	692	133/414	0.32 (0.28, 0.37)	272/278	0.98 (0.95, 0.99)	0.96 (0.91, 0.98)	0.49 (0.45, 0.53)	14.88 (6.66, 33.25)	0.69 (0.65, 0.74)
S/A PR-EPTBW		•		•					
MRS	53	2/6	0.33 (0.04, 0.78)	41/47	0.87 (0.74, 0.95)	0.25 (0.03, 0.65)	0.91 (0.79, 0.98)	2.61 (0.67, 10.13)	0.76 (0.43, 1.36)
Xpert Ultra*	22	2/5	0.40 (0.05, 0.85)	11/17	0.65 (0.38, 0.86)	0.25 (0.03, 0.65)	0.79 (0.49, 0.95)	1.13 (0.32, 3.96)	0.93 (0.42, 2.06)
MGIT	53	1/3	0.33 (0.01, 0.91)	43/50	0.86 (0.73, 0.94)	0.12 (0, 0.53)	0.96 (0.85, 0.99)	2.38 (0.42, 13.59)	0.78 (0.35, 1.74)
CRS	53	8/33	0.24 (0.11, 0.42))	20/20	1.00 (0.83, 1.00)	1.00 (0.63, 1.00)	0.44 (0.30, 0.60)	Inf (NA, Inf)	0.76 (0.62, 0.92)
F/A PR-PTBW									
MRS	692	137/335	0.41 (0.36, 0.46)	282/357	0.79 (0.74, 0.83)	0.65 (0.58, 0.71)	0.59 (0.54, 0.63)	1.95 (1.53, 2.47)	0.75 (0.67, 0.83)
Xpert Ultra	692	124/300	0.41 (0.36, 0.47)	304/392	0.78 (0.73, 0.82)	0.58 (0.52, 0.65)	0.63 (0.59, 0.68)	1.84 (1.47, 2.31)	0.76 (0.68, 0.84)
MGIT ^{\$}	655	118/280	0.42 (0.36, 0.48)	290/375	0.77 (0.73, 0.81)	0.58 (0.51, 0.65)	0.64 (0.60, 0.69)	1.86 (1.47, 2.34)	0.75 (0.67, 0.84)
CRS	692	154/414	0.37 (0.33, 0.42)	220/278	0.79 (0.74, 0.84)	0.73 (0.66, 0.79)	0.46 (0.41, 0.50)	1.78 (1.37, 2.31)	0.79 (0.72, 0.87)v
F/A PR-EPTBW									
MRS	53	3/6	0.50 (0.12, 0.88)	32/47	0.68 (0.53, 0.81)	0.17 (0.04, 0.41)	0.91 (0.77, 0.98)	1.57 (0.64, 3.86)	0.73 (0.32, 1.67)
Xpert Ultra*	22	2/5	0.40 (0.05, 0.85)	11/17	0.65 (0.38, 0.86)	0.25 (0.03, 0.65)	0.79 (0.49, 0.95)	1.13 (0.32, 3.96)	0.93 (0.42, 2.06)
MGIT ^{\$}	53	2/3	0.67 (0.09, 0.99)	34/50	0.68 (0.53, 0.80)	0.11 (0.01, 0.35)	0.97 (0.85, 1)	2.08 (0.85, 5.11)	0.49 (0.10, 2.46)
CRS	53	13/33	0.39	15/20	0.75	0.72	0.43	1.58	0.81

262 presumed extra pulmonary tuberculosis from ward.

263

^{\$} Participants with inadequate specimen, NTM, or not ordered set to missing for culture only reference standard.

^{*}22 participants had a non-sputum sample taken for Xpert Ultra testing for EPTB; participants with a sputum sample taken

were excluded from analysis. The 22 shown due to having a non-sputum sample for Xpert Ultra testing are likely not a random

sample of the total 53 participants in the table, and diagnostic performance estimates should be interpreted with caution.

268	When evaluating the diagnostic performance of uLAM detection using the F/A pair, sensitivity
269	was 41% (95% CI: 36-46%) in PR-PTBW, and 50% (95% CI: 12-88%) in PR-EPTBW group (<i>p</i> =0.693) (Table
270	3). True negatives may have been somewhat more accurately identified using F/A in PR-PTBW
271	(Specificity: 79%, 95% CI: 74-83%) compared to PR-EPTBW (Specificity: 68%, 95% CI: 53-81%, <i>p</i> =0.096).
272	When comparing performance using the CRS as the reference standard, F/A test sensitivity and
273	specificity were very similar in PR-PTBW and PR-EPTBW, with sensitivity of 37%-39% and specificity of
274	75-79%.

When assessing performance between the S/A and F/A Ab pairs, their sensitivity was similar in

275

276 the PR-PTBW (p=0.356). However, the S/A pair had significantly higher specificity (97% vs 79%, 277 p<0.0001) and PPV (94% vs 65%, p<0.0001). Similar diagnostic performances were observed between 278 both Ab pairs in PR-PTBW when using CRS as the reference standard. Amongst PR-EPTBW, while 279 sensitivity against MRS appeared to be slightly higher with F/A, a detectable difference in performance 280 was not observed in this small EPTB MRS positive group (n=6, 50% vs 33%, p>0.99). However, specificity 281 was higher for the S/A than for F/A pair (87% vs 68%, p=0.039) in PR-EPTBW. When comparing the 282 discriminatory ability at varying estimated concentration thresholds, the S/A pair showed greater 283 discriminatory ability compared to F/A pair in PR-PTBW (area under the curve [AUC]=0.744 vs 0.628, 284 p<0.0001) and PR-EPTBW (AUC=0.755 vs 0.5339, p=0.045) (Figure 3). 285 Figure 3. Receiver operating characteristic curves comparing estimated uLAM concentrations (pg/mL) 286 derived from the S/A and F/A Ab pairs to microbiological reference standard (MRS), all groups. 287 Receiver operating curves comparing the ECL immunoassay uLAM concentrations to the MRS, using 2 288 separate antibody pairs for both PR-PTBW & PR-EPTBW. Comparison to the MRS using the S4-20:A194-289 01 (S/A) pair is shown in blue, with performance PR-PTBW (AUC=0.744, n=692) shown in the solid line

and performance in PR-EPTBW (AUC=0.755, n=53) shown in the dashed line. Comparison to the MRS

using the FIND 28:A194-01 (F/A) pair is shown in green, with performance in PR-PTBW (AUC, 0.628,
n=692) shown in the solid line and performance in PR-EPTBW (AUC=0.539, n=53) shown in the dashed
line. Discriminatory ability using the S4-20:A194-01 Ab pair was high for both PR-PTBW & PR-EPTBW
compared to the FIND-28:A194-01 pair.

295

296 Discussion

297 We have completed the largest study to date on a HIV negative cohort presenting with 298 presumptive TB disease wherein we assessed the diagnostic performance of a highly sensitive 299 immunoassay platform to detect the levels of uLAM from urine as compared to the MRS. In a cohort of 300 HIV-uninfected adults with either presumptive PTB or EPTB disease, uLAM was detectable in less than 301 half of people and the concentrations observed were typically low. The F/A pair had slightly higher 302 sensitivity than the S/A pair (41% vs. 39%) but also had a much lower specificity (79% vs. 97%). The 303 routine standard of care included sputum smear microscopy wherein the majority of PTB patients were sputum smear-negative (18.9% smear positivity), suggesting that a large proportion of participants in 304 305 this study had subclinical TB with a relatively low bacterial disease burden and thus less availability of 306 LAM at the site of infection and potentially also in the urine. Others have also noted significant 307 differences in uLAM levels based on the geographical sites, presumably highlighting that different TB 308 lineages may affect the levels of uLAM observed in patient urine [15,19]. We also investigated the 309 performance of the immunoassays with urine collected from either pulmonary or EPTB. No significant 310 differences was seen between these groups with either antibody pair although it should be noted the 311 size of the EPTB group (N = 53, MRS TB positive 6) was much smaller than the PTB group (N = 692, MRS 312 TB positive 335).

313 Many previous cohorts that have been screened for uLAM in urine typically have a higher 314 prevalence of HIV positive comorbidity and as such often have higher concentrations of uLAM in their 315 urine. The results from this study are less optimistic than from other studies who reported significantly 316 higher sensitivities when detecting uLAM in HIV negative cohorts [24–26]. Broger et al analyzed 317 concentrated urine from 372 HIV-negative participants from Peru and South Africa using the S/A assay 318 on the MSD platform with the pooled performance data having a sensitivity of 66.7% (95% CI 57.5%-319 74.7%) and a specificity of 98.1% (95% CI 95.6%-99.2%) [19]. It was also noted in the supplemental data 320 in a subgroup analysis that the sensitivity was much higher in Peru (78.5%) compared with South Africa 321 (37.5%), with specificities of 100% and 95.3% respectively, the latter data reflecting that the poor 322 sensitivity of uLAM detection on the MSD platform has been observed [19]. While we used the same 323 platform and ECL assays as previously used in an earlier smaller scale study on an HIV negative cohort 324 [20], we used a different methodology for establishing the cut off. In the work by Sigal et al. they 325 assigned cut off value of 11 pg/mL to the S/A assay results [20], while Broger et al used a cutoff of 5.4 326 pg/mL [19], noting that such a cutoff would not be applicable to other LAM assays. Where a cutoff 327 allows for practicality and comparative analysis, using this ultrasensitive method for uLAM is still 328 relatively new. Furthermore, using plate based LOD allows for a more standardized and objective 329 measure of a given analyte, especially one as heterogenous as LAM [9,15,25], where there are inherent 330 differences in the antibody pairs being assessed respective to sensitivity and specificity. Once use of a 331 specific antibody pair is normalized, a generalizable cutoff would be expeditious in studying LAM in 332 various populations. The negative association of glycosuria on uLAM concentration with A194-01 and an 333 S4-20 derivative has been noted, we did not perform urinalysis on the samples used and so a greater 334 proportion of participants with glycosuria would influence our results [25].

Other studies have measured uLAM using different methods. One study reported the use of
 nanocages hosting a dye as the capture ligand in association with three detector antibodies including

337 A194-01 and MoAB1, a recombinant derivative of S4-20 [27]. The nanocages offered a 50-fold increase 338 in uLAM concentration and overall, the pooled diagnostic accuracy from the three antibodies was 90% 339 sensitivity at 73.5% specificity [25,27]. A further study had 160 participants who were predominantly 340 HIV negative and this study also reported very high sensitivity and specificity using the antibody pair CS-341 35/A194-01 but the authors acknowledge that the study focused on predominantly TB positive cohorts 342 (140 TB positive from 160 samples, many of which were smear 1+ or greater) and so diagnostic accuracy 343 was not established due to the low number of TB negative cases included (N = 10) [28]. This study also 344 included proteinase K pretreatment and mild heating (55°C) which significantly improved the 345 sensitivities of the immunoassay used. In addition, all samples were derived for Peru and we speculate 346 that this data augments the observations for Broger et al where significantly more uLAM was seen in 347 samples from this country.

There are several limitations to this study. First, all of the ECL testing was conducted on 348 349 previously frozen and not fresh urine specimens. While banked samples are more convenient for high 350 throughput testing, long-term freezing may diminish uLAM levels [29,30]. While samples were 351 maintained at -80°C on the day of collection until the time of testing, we did not assess the time from 352 specimen collection to freezing. The clinical laboratory protocol did note to store the samples at 4°C 353 soon after collection and to then store aliquots at -80°C once 15 mL conical tubes had been filled. There 354 may also have been additive effects caused by the COVID-19 pandemic on exposure risk to TB while 355 under lock down and in changes to care seeking behaviors due to the pandemic. The powered 356 calculations for the study protocol were based on pre-pandemic national TB prevalence rates wherein 357 an estimated 271 confirmed TB positive cases would be identified within a cohort of 780. Further, 358 greater awareness of the risks of respiratory disease may have induced earlier care seeking in some 359 cases and as such cases of TB were identified earlier and in addition lack of access to care during lock 360 downs may have led to cases of self-clearance of TB.

361 The predominant lineage of the *Mycobacterium tuberculosis* strain may also play a role in 362 variation of the median level of uLAM detected [15,25]. In this work, we also took a slightly different 363 approach to ascribing a detection threshold to score the presence of uLAM based on the LOD 364 determined on a plate-by-plate basis via each standard curve versus a uniform cut off for all data [19-365 20]. While we have confidence in the quality of the data generated to describe the PTB cohort based on 366 the number of participants and the relative ease with which diagnostic results could be applied to score 367 as PTB or TB negative. The study was not designed to enroll a sufficient number of PR-EPTBW to allow 368 statistical comparisons between PR-EPTBW and PR-PTBW; 53 versus 692 respectively and added to this 369 were limitations in the collection and use of appropriate samples to microbiologically confirm EPTB 370 diagnosis. Finally, the prevalence of bacteriologically confirmed TB is higher than expected in a 371 population of presumptive adults presenting at both outpatient and inpatient settings. It is important to 372 note that study enrollment coincided with Vietnam's surge in SARS-CoV-2 infections associated with the 373 spread of the Omicron variant, which could have potentially affected healthcare-seeking behavior due 374 to mobility restrictions and increased screening at health facilities. This could potentially explain the low 375 proportion of reported febrile illness observed in this cohort, and could potentially result in patients 376 only seeking care with increased TB disease severity. However, the higher proportion of AFB smear 377 microscopy results with scanty/1+ grading indicate that this may not be the case. Nonetheless, it is 378 important to take this into consideration when evaluating the positive and negative predictive test 379 values, which are influenced by underlying disease prevalence.

Biomolecules in urine samples may present challenges to sensitivity, and several studies have investigated specimen preparation methods to improve access for the antibody to its target epitope [31]. Improved methods include specimen preparation via enzymatic or inhibitor specific treatments to release sequestered uLAM from complexes or remove inhibitory compounds such as lipids or proteinuLAM complexes [32–34]. The enrichment of uLAM concentration in urine specimens has been achieved

385	via a variety of methods using either the direct capture of uLAM via specific antibodies [35,36], a uLAM
386	specific chemical ligand or via proteolysis, chemical treatment and ultrafiltration [27,37]. Others have
387	focused on improving high sensitivity assays via platform improvement, novel antibodies, and the
388	application of machine learning algorithms to improve diagnostic accuracy [38–40]. The application of
389	multiple antibodies, each targeting different LAM epitopes, has also been demonstrated to increase
390	diagnostic performance [25]. A key component to this work is to ensure that clinical samples are used
391	early in the product development phase and that clinical evaluation should encompass multiple
392	populations as evidenced in this and other work where the detection of uLAM in the urine of TB positive
393	HIV negative patients varies [19,28,38].
394	In conclusion, from a large HIV-negative cohort in Vietnam, high-sensitivity immunoassay testing
395	for uLAM did not reach the levels noted in the TPP criteria for an effective diagnostic test for TB disease.
396	Developing a better uLAM assay to diagnose the majority of people with TB disease may require novel
397	antibodies, a urine concentration step, or both. Nonetheless, developing non-sputum based RDTs to

398 diagnose people with TB disease needs to remain a global health priority.

399 References

- Getahun H, Ford N. Tackling the persistent burden of tuberculosis among people living with HIV. J
 Int AIDS Soc. 2016;19: 21002. doi:10.7448/IAS.19.1.21002
- Global tuberculosis report 2022. [cited 1 May 2023]. Available: https://www.who.int/publications detail-redirect/9789240061729
- UNITAID 2017 TUBERCULOSIS Diagnostics Technology Landscape 5th Edition, May 2017. [cited 1
 May 2023]. Available: https://unitaid.org/assets/2017-Unitaid-TB-Diagnostics-Technology Landscape.pdf
- Flores J, Cancino JC, Chavez-Galan L. Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of
 Tuberculosis: How Far Are We to Use It? Front Microbiol. 2021;12: 638047.
 doi:10.3389/fmicb.2021.638047
- 410 5. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages
 411 infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo.
 412 Blood. 2007;110: 3234–3244. doi:10.1182/blood-2007-03-079152
- Cheng Y, Schorey JS. Exosomes carrying mycobacterial antigens can protect mice against
 Mycobacterium tuberculosis infection. Eur J Immunol. 2013;43: 3279–3290.
 doi:10.1002/eji.201343727
- 416 7. Hamasur B, Bruchfeld J, Haile M, Pawlowski A, Bjorvatn B, Källenius G, et al. Rapid diagnosis of
 417 tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Microbiol Methods.
 418 2001;45: 41–52. doi:10.1016/s0167-7012(01)00239-1
- Corrigan DT, Ishida E, Chatterjee D, Lowary TL, Achkar JM. Monoclonal antibodies to
 lipoarabinomannan/arabinomannan characteristics and implications for tuberculosis research
 and diagnostics. Trends Microbiol. 2022; S0966-842X(22)00174–3. doi:10.1016/j.tim.2022.07.001
- Choudhary A, Patel D, Honnen W, Lai Z, Prattipati RS, Zheng RB, et al. Characterization of the
 Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of Mycobacterium
 tuberculosis, and Complexity of Antibody Specificities toward This Antigen. J Immunol. 2018;200:
 3053–3066. doi:10.4049/jimmunol.1701673
- 426 10. World Health Organization, Others. High-priority target product profiles for new tuberculosis
 427 diagnostics: report of a consensus meeting. Geneva, Switzerland: WHO; 2014.
- World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for
 the diagnosis and screening of active tuberculosis in people living with HIV. Policy Guidance.
 Geneva, Switzerland; 2015 p. 63. Available: https://www.who.int/tb/areas-ofwork/laboratory/policy statement lam web.pdf
- 432 12. World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis
 433 of active tuberculosis in people living with HIV. Policy update. Genera; 2019 p. 28.

434 World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: 13. 435 rapid diagnostics for tuberculosis detection. 2021 update. Geneva: World Health Organization; 436 2021. Available: https://apps.who.int/iris/handle/10665/342331 437 14. WHO updates policy for the use of lateral flow urine lipoarabinomannan assay (LF-LAM) for 438 diagnosing active tuberculosis in people living with HIV. [cited 12 Jun 2023]. Available: 439 https://www.who.int/news/item/04-11-2019-who-updates-policy-for-the-use-of-lateral-flow-440 urine-lipoarabinomannan-assay-(lf-lam) 441 De P, Amin AG, Flores D, Simpson A, Dobos K, Chatterjee D. Structural implications of 15. 442 lipoarabinomannan glycans from global clinical isolates in diagnosis of Mycobacterium tuberculosis infection. J Biol Chem. 2021;297: 101265. doi:10.1016/j.jbc.2021.101265 443 444 De P, Shi L, Boot C, Ordway D, McNeil M, Chatterjee D. Comparative Structural Study of Terminal 16. 445 Ends of Lipoarabinomannan from Mice Infected Lung Tissues and Urine of a Tuberculosis Positive 446 Patient. ACS Infect Dis. 2020;6: 291–301. doi:10.1021/acsinfecdis.9b00355 447 17. Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, et al. Lateral flow 448 urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. 449 Cochrane Database Syst Rev. 2019;10: CD011420. doi:10.1002/14651858.CD011420.pub3 18. 450 Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral flow urine 451 lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane 452 Database Syst Rev. 2016;2016: CD011420. doi:10.1002/14651858.CD011420.pub2 453 Broger T, Nicol MP, Sigal GB, Gotuzzo E, Zimmer AJ, Surtie S, et al. Diagnostic accuracy of 3 urine 19. 454 lipoarabinomannan tuberculosis assays in HIV-negative outpatients. J Clin Invest. 2020;130: 5756-455 5764. doi:10.1172/JCI140461 456 Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, et al. A Novel Sensitive Immunoassay 20. 457 Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's 458 Performance Target for Tuberculosis Diagnosis. J Clin Microbiol. 2018;56. doi:10.1128/JCM.01338-459 18 460 21. Kawasaki M, Echiverri C, Raymond L, Cadena E, Reside E, Gler MT, et al. Lipoarabinomannan in 461 sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: 462 Analytic validation and evaluation in two cohorts. PLOS Med. 2019;16: e1002780. 463 doi:10.1371/journal.pmed.1002780 464 Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: Display and Analyze ROC 22. 465 Curves. 2023. Available: https://cran.r-project.org/web/packages/pROC/index.html 466 R Core Team (2021). R: A language and environment for statistical computing. Vienna, Austria.: R 23. 467 Foundation for Statistical Computing; Available: URL https://www.R-project.org/ 468 24. Amin AG, De P, Spencer JS, Brennan PJ, Daum J, Andre BG, et al. Detection of lipoarabinomannan 469 in urine and serum of HIV-positive and HIV-negative TB suspects using an improved capture-470 enzyme linked immuno absorbent assay and gas chromatography/mass spectrometry. Tuberc 471 Edinb. 2018;111: 178-187. doi:10.1016/j.tube.2018.06.004

472 25. Magni R, Rruga F, Alsaab F, Sharif S, Howard M, Espina V, et al. Lipoarabinomannan antigenic
473 epitope differences in tuberculosis disease subtypes. Sci Rep. 2020;10: 13944.
474 doi:10.1038/s41598-020-70669-9

Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, et al. Biomarkers of Tuberculosis
Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.
EBioMedicine. 2017;25: 112–121. doi:10.1016/j.ebiom.2017.10.018

Paris L, Magni R, Zaidi F, Araujo R, Saini N, Harpole M, et al. Urine lipoarabinomannan glycan in
HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl
Med. 2017;9. doi:10.1126/scitranslmed.aal2807

481 28. Amin AG, De P, Graham B, Calderon RI, Franke MF, Chatterjee D. Urine lipoarabinomannan in HIV
482 uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a
483 sensitive immunoassay and mass spectrometry. Sci Rep. 2021;11: 2922. doi:10.1038/s41598-021484 82445-4

485 29. Broger T, Muyoyeta M, Kerkhoff AD, Denkinger CM, Moreau E. Tuberculosis test results using fresh
486 versus biobanked urine samples with FujiLAM. Lancet Infect Dis. 2020;20: 22–23.
487 doi:10.1016/S1473-3099(19)30684-X

488 30. Connelly JT, Grant B, Munsamy V, Pym A, Somoskovi A. Lipoarabinomannan point-of-care tests:
489 evaluation with fresh samples needed. Lancet Infect Dis. 2019;19: 1053. doi:10.1016/S1473490 3099(19)30475-X

491 31. Correia-Neves M, Fröberg G, Korshun L, Viegas S, Vaz P, Ramanlal N, et al. Biomarkers for
492 tuberculosis: the case for lipoarabinomannan. ERJ Open Res. 2019;5.
493 doi:10.1183/23120541.00115-2018

494 32. García JI, Kelley HV, Meléndez J, de León RAA, Castillo A, Sidiki S, et al. Improved Alere Determine
495 Lipoarabinomannan Antigen Detection Test for the Diagnosis of Human and Bovine Tuberculosis
496 by Manipulating Urine and Milk. Sci Rep. 2019;9: 18012. doi:10.1038/s41598-019-54537-9

497 33. Hamasur, B. SpeClean: urine sample treatment method for ultra-sensitive LAM diagnostics. Poster.
498 50th Union World Conference on Lung Health; 2019; Hyderabad, India.

Panraksa Y, Amin AG, Graham B, Henry CS, Chatterjee D. Immobilization of Proteinase K for urine
 pretreatment to improve diagnostic accuracy of active tuberculosis. PloS One. 2021;16: e0257615.
 doi:10.1371/journal.pone.0257615

Solation
 Solation<

 Shapiro A, Wittwer T, Ngwane N, Magcaba Z, Mullins B, Aamotsbakken R, et al. A point-of-care test to concentrate and detect urine LAM for TB diagnosis: results from the first-in-human study of
 FLOW-TB. Abstract presented at: 50th World Conference on Lung Health of the International
 Union Against Tuberculosis and Lung Disease. 2019.

- S7. Cantera JL, Rashid AA, Lillis LM, Peck RB, Drain PK, Shapiro AE, et al. Isolation and purification of
 lipoarabinomannan from urine of adults with active TB. Int J Tuberc Lung Dis Off J Int Union Tuberc
 Lung Dis. 2023;27: 75–77. doi:10.5588/ijtld.22.0372
- Sa. Cantera JL, Lillis LM, Peck RB, Moreau E, Schouten JA, Davis P, et al. Performance of novel
 antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis.
 PLoS ONE. 2022;17. doi:10.1371/journal.pone.0274415
- Huang Y, Darr CM, Gangopadhyay K, Gangopadhyay S, Bok S, Chakraborty S. Applications of
 machine learning tools for ultra-sensitive detection of lipoarabinomannan with plasmonic grating
 biosensors in clinical samples of tuberculosis. PloS One. 2022;17: e0275658.
 doi:10.1371/journal.pone.0275658
- 40. Wood A, Barizuddin S, Darr CM, Mathai CJ, Ball A, Minch K, et al. Ultrasensitive detection of
 lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients
 with tuberculosis. PloS One. 2019;14: e0214161. doi:10.1371/journal.pone.0214161

522 Acknowledgements

- 523 The project team would like to thank each of the participants in this study for their willingness to enroll,
- 524 provide urine samples to support this work, and to permit the use of their test data. We would also like
- 525 to acknowledge the staff of the National Lung Hospital of Hanoi for their dedication and commitment to
- 526 the implementation and operation of this project.

527 Supplemental Materials

528 Tables

- 529 **S1** Table. The diagnostic sensitivity and specificity of the pooled ECL immunoassays antibody pairs.
- 530 The PR-PTBW and PR-EPTBW groups compared to the MRS, Xpert, MGIT and the CRS were used for the
- 531 diagnosis of active TB. Abbreviations: N, number; TP, true positive; TN, true negative; FN, false negative;
- 532 FP, false positive; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value;
- 533 PLR, positive likelihood ratio; NLR, negative likelihood ratio S/A, S4-20/A194-01; F/A, FIND28/A194-01;
- 534 PR-PTBW, presumed pulmonary tuberculosis from ward; MGIT, mycobacterial growth indicator tube;
- 535 MRS, microbiological reference standard; CRS, clinical reference standard; PR-EPTBW, presumed extra

536	pulmonary	tuberculosis	from wa	rd; N/A,	not applicabl	e
				, , ,		

		Positive by reference standard		Negative by reference standard					
Reference Standard	n	TP/TP+FN	Sensitivity (95% CI)	TN/TN+FP	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	PLR (95% CI)	NLR (95% CI)
PR-PTBW									
MRS	692	184/335	0.55 (0.49, 0.60)	277/357	0.78 (0.73, 0.82)	0.70 (0.64, 0.75)	0.65 (0.60, 0.69)	2.45 (1.97, 3.04)	0.58 (0.51, 0.66)
Xpert Ultra	692	169/300	0.56 (0.51, 0.62)	297/392	0.76 (0.71, 0.80)	0.64 (0.58, 0.70)	0.69 (0.65, 0.74)	2.32 (1.90, 2.84)	0.58 (0.50, 0.66)
MGIT ^{\$}	655	159/280	0.57 (0.51, 0.63)	283/375	0.75 (0.71, 0.80)	0.63 (0.57, 0.69)	0.70 (0.65, 0.74)	2.31 (1.89, 2.84)	0.57 (0.49, 0.66)
CRS	692	203/414	0.49 (0.44, 0.54)	217/278	0.78 (0.73, 0.83)	0.77 (0.71, 0.82)	0.51 (0.46, 0.56)	2.23 (1.75, 2.85)	0.65 (0.58, 0.73)
PR-EPTBW									
MRS	53	3/6	0.50 (0.12, 0.88)	29/47	0.62 (0.46, 0.75)	0.14 (0.03, 0.36)	0.91 (0.75, 0.98)	1.31 (0.54, 3.14)	0.81 (0.35, 1.86)
Xpert Ultra*	22	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGIT	53	2/3	0.67 (0.09, 0.99)	31/50	0.62 (0.47, 0.75)	0.10 (0.01, 0.30)	0.97 (0.84, 1.00)	1.75 (0.73, 4.21)	0.54 (0.11, 2.70)
CRS	53	16/33	0.48 (0.31, 0.66)	15/20	0.75 (0.51, 0.91)	0.76 (0.53, 0.92)	0.47 (0.29, 0.65)	1.94 (0.84, 4.48)	0.69 (0.45, 1.04)

^{\$}Participants with inadequate specimen, NTM, or not ordered set to missing for culture only reference standard.

538 £1 participant excluded due to invalid result using visual assessment criteria.

^{*}22 participants had a non-sputum sample taken for Xpert Ultra testing; participants with a sputum sample taken were

540 excluded from analysis. The 22 shown due to having a non-sputum sample for Xpert Ultra testing are likely not a random

sample of the total 53 participants in the table, and diagnostic performance estimates should be interpreted with caution.

543 S2 Table. Plate lower limits of detection (LLOD) of PR-PTBW participants. The LLODs from the

- 544 immunoassay plates used for uLAM quantitation using the S4-20/A194-01 immunoassay stratified by
- 545 MRS status from the PR-PTBW group (n=692). Abbreviations: N, number; MRS, microbiological reference
- 546 standard; N/A, not applicable.

LLOD	n (%)	uLAM Detected (n=	139)	uLAM Not Detected (n=553)			
(pg/mL)	11 (70)	Mean (min, max)	n	Mean (min, max)	n		
10	16	129.5 (22, 346)	4	0.1 (0,1)	12		
11	111	162.0 (12, 2160)	27	1.1 (0, 8)	84		
12	39	902.8 (17 <i>,</i> 7039)	10	1.1 (0, 10)	29		
13	79	224.0 (31, 599)	8	1.5 (0, 8)	71		
15	57	216.9 (15, 1691)	13	1.2 (0, 10)	44		
16	34	197.2 (17, 2138)	15	3.3 (0, 12)	19		
17	39	1582.7 (21, 9244)	6	1.6 (0, 11)	33		
18	117	404.0 (18, 6017)	24	2.1 (0, 16)	93		
19	37	12443.3 (41, 36994)	3	2.4 (0, 14)	34		
21	75	82.2 (21, 299)	16	1.8 (0, 16)	59		
22	8	32.0 (32, 32)	1	1.9 (0, 11)	7		
23	38	653.5 (71, 1236)	2	2.5 (0, 14)	36		
26	39	369.6 (27, 1235)	7	3.3 (0, 18)	32		
52	1	69.0 (69, 69)	1	NA	0		
63	2	94 5 (68 121)	2	NA	0		

559 S3 Table. Plate lower limits of detection (LLOD) of PR-EPTBW participants. The LLOD from the

- 560 immunoassay plates used for uLAM quantitation using the S4-20/A194-01 immunoassay stratified by
- 561 MRS status from the PR-EPTBW group (N=53). Abbreviations: N, number; MRS, microbiological
- 562 reference standard; N/A, not applicable.
- 563

LLOD (pg/mL)	n (%)	LAM Detected (n=8)				LAM Not Detected (n=45)				
		MRS Positive (n=2)		MRS Negative		MRS Positive (n=2)		MRS Negative (n=6)		
		Mean (min. max)	n	Mean (min. max)	n	Mean (min. max)	n	Mean (min. max)	n	
10	4 (7.5)	-	0	-	0	-	0	0.5 (0, 2)	4	
13	1 (1.9)	-	0	-	0	10.0 (10, 10)	1	-	0	
16	4 (7.5)	51.0 (51, 51)	1	24.0 (18, 34)	3	-	0	-	0	
22	26 (49.1)	50.0 (50, 50)	1	-	0	4.0 (4, 4)	1	1.9 (0, 15)	24	
27	18 (34)	-	0	38.3 (32, 45)	3	7.5 (0, 15)	2	5.5 (0, 21)	13	

564

- 565
- 566

567 S1 Fig. Urine Log LAM concentration by the ECL immunoassay using antibody pairs S/A and F/A

568 (N=745). A comparison of the distribution of estimated uLAM concentrations for the same participants

using S/A and F/A the two antibody pairs.

570

571 **S1 Doc. Participant inclusion and exclusion criteria.**

572

573 S2 Doc. Study Procedures



Figure 1



Figure 2



Figure 3